Radio-/Chemotherapie des PankreaskarzinomsRadio-/Chemotherapy of pancreas carcinoma - PaCa

• Conditions: patients with adenocarcinoma of the pancreas; MedDRA version: 12.1Level: LLTClassification code 10052747Term: Adenocarcinoma pancreas

• Registration Number: EUCTR2009-011968-11-DE
• Lead Sponsor: Technische Universität Dresden

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-05-31
• Last Update Posted: 12 January 2015

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

patients with adenocarcinoma of the pancreas UICC stadium I-III without metastases
Karnofsky-Index of 80 and more
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

carcinoma of the ampulla vateri
carcinoma located in the tail or engaging more than 50 % of the corpus
carcinoma of the pancreas other than adenocarcinoma
previous tumor specific treatment
relapse of a tumor
metastases
carcinosis of the peritoneum
cirrhosis of the liver
Serumcreatinine more than 1,5 mg/dl, Creatinine-Clearance less than 70 ml/min
severe cardiopulmonary diseases
HIV Infection
Necessarity of immunosuppression
serious wounds, ulcera or fractures that do not heal
myelosuppression before the beginning of the therapy with Oxaliplatine, proven by neutrocytes less than 2 x 10E9/l and/or thrombocytes less than 100 x 10E9/l
peripheric sensoric neuropathia with functionary loss before the beginning of the therapy with Oxaliplatine
patients with ferromagnetic implants

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified